Buy Abbott India: target of Rs 22,780: Sharekhan

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Sharekhan's research report on Abbott India

Abbott India Limiteds (Abbott) revenues and PAT are expected to grow in double digits over next two years, led by healthy growth in IPM, presence in high-growth therapy areas and strong performance of top brands. Sustained growth and leadership from existing brands, product portfolio expansion, efforts to improve the reach and penetration would be the key drivers. Leveraging the digital platform to cost-effectively improve geographic penetration also bodes well.

Outlook

Given the strong growth prospects & financials and a sturdy dividend payout we re-iterate our Buy recommendation on Abbott with an unchanged PT of Rs. 22,780.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More